Neuropeptide Abnormalities in Patients With Early Alzheimer Disease
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Deficits in somatostatin-like immunoreactivity (SLI) and corticotropin-releasing factor immunoreactivity (CRF-IR) are well recognized as prominent neurochemical deficits in Alzheimer disease (AD). The question of whether these profound neuropeptidergic deficits found in patients with end-stage disease extend into those with much earlier disease is relatively unanswered. To determine the relation between level of SLI and CRF-IR in different cerebrocortical regions to the earliest signs of cognitive deterioration in AD. METHODS: We examined SLI and CRF-IR levels in 9 neocortical brain regions of 66 elderly patients in a postmortem study of nursing home residents who had either no significant neuropathologic lesions or lesions associated only with AD. Patients were assessed by the Clinical Dementia Rating scale (CDR) to have no dementia or questionable, mild, or moderate dementia, and were compared with 15 patients with severe dementia. RESULTS: Both CRF-IR and SLI were significantly reduced in the cortices of patients with the most severe dementia, but only the levels of CRF-IR were reduced in those with mild (CDR = 1.0) and moderate dementia (CDR = 2.0). Levels of CRF-IR and SLI correlated significantly with CDR, but this correlation was more robust for CRF-IR and persisted even when severely cognitively impaired patients were eliminated from analysis. CONCLUSIONS: Although SLI and CRF-IR levels are significantly reduced in patients with severe dementia, only CRF-IR is reduced significantly in the cortices of those with mild dementia. Thus, CRF-IR can serve as a potential neurochemical marker of early dementia and possibly early AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Davies, P., Katzman, R., & Terry, R. D. (1980) · Nature · doi:10.1038/288279a0 · Cited by 882 · cited 2×
“The somatostatin antisera are directed toward residues 6 to 10 of the somatostatin (1-14) molecule and recognize somatostatin (1-14) and somatostatin (1-28) on an equimolar basis.”
BackgroundMethodHaroutunian, V. (1998) · Archives of Neurology · doi:10.1001/archneur.55.9.1185 · Cited by 289
Self-citationSomatostatin immunoreactivity in neuritic plaques of Alzheimer's patients
Morrison, J. H., Rogers, J., Scherr, S., Benoit, R., & Bloom, F. E. (1985) · Nature · doi:10.1038/314090a0 · Cited by 264 · cited 1×
“The somatostatin antisera are directed toward residues 6 to 10 of the somatostatin (1-14) molecule and recognize somatostatin (1-14) and somatostatin (1-28) on an equimolar basis.”
BackgroundNeurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease
Haroutunian, V., Purohit, D. P., Perl, D. P., Marin, D., Khan, K., Lantz, M., Davis, K. L., & Mohs, R. C. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.713 · Cited by 201
Self-citationBissette, G., Cook, L., Smith, W., Dole, K. C., Crain, B., & Nemeroff, C. B. (1998) · Journal of Alzheimer’s Disease · doi:10.3233/jad-1998-1203 · Cited by 20
Cited by
Role of Corticotropin-Releasing Factor in Drug Addiction: Potential for Pharmacological Intervention
Logrip, M. L., Koob, G. F., & Zorrilla, E. P. (2011) · CNS Drugs · doi:10.2165/11587790-000000000-00000 · Cited by 476
Plasma Cortisol and Progression of Dementia in Subjects With Alzheimer-Type Dementia
Csernansky, J. G., Dong, H., Fagan, A. M., Wang, L., Xiong, C., Holtzman, D. M., & Morris, J. C. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2164 · Cited by 426
Corticotropin-Releasing Factor in Brain: A Role in Activation, Arousal, and Affect Regulation
Heinrichs, S. C., & Koob, G. F. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.052092 · Cited by 353
“Thus, CRF decrements may reflect changes associated with early dementia and possibly early Alzheimer’s disease (Davis et al., 1999).”
BackgroundThe Role of Corticotropin-Releasing Factor in Drug Addiction
Sarnyai, Z., Shaham, Y., & Heinrichs, S. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01492-3 · Cited by 351
Regulation and function of somatostatin receptors
Olias, G., Viollet, C., Kusserow, H., Epelbaum, J., & Meyerhof, W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02402.x · Cited by 318
Metadata
- Authors
- Davis, K. L., Mohs, R. C., Marin, D. B., Purohit, D. P., Perl, D. P., Lantz, M., Austin, G., & Haroutunian, V.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1999-11-01
- Volume
- 56
- Issue
- 11
- Pages
- 981
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2120062924
- Cited by
- 72
- References
- 5
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuropeptide Abnormalities in Patients With Early Alzheimer Disease. https://app.cochat.ai/papers/10.1001/archpsyc.56.11.981
- The paper
- Davis, K. L., Mohs, R. C., Marin, D. B., Purohit, D. P., Perl, D. P., Lantz, M., Austin, G., & Haroutunian, V. (1999). Neuropeptide Abnormalities in Patients With Early Alzheimer Disease. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.56.11.981
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.